ArriVent BioPharma (AVBP) saw its stock price surge 5.21% during Wednesday's trading session, as investors show optimism ahead of the company's upcoming fourth-quarter earnings report. The biotechnology firm is scheduled to release its financial results on Thursday, according to the latest earnings calendar.

The significant uptick in ArriVent's stock price suggests that market participants may be anticipating positive news or strong financial performance from the company. Biotech stocks often experience heightened volatility around earnings announcements, as these reports provide crucial insights into the company's progress in drug development, clinical trials, and overall financial health.

While specific analyst expectations for ArriVent's Q4 results were not provided, the stock's pre-earnings rally indicates a bullish sentiment among investors. Shareholders and market watchers will be closely monitoring the earnings release for updates on the company's pipeline, any potential regulatory milestones, and financial metrics that could justify the recent stock price movement.